Driven by 20 years in the military, the CEO of Theradaptive hopes his firm’s regenerative “paint” technology platform can transform bone repair, spinal fusion, and sports medicine.
The Boston-based firm, spun out of MIT, has a computational platform it says turns recombinant proteins into material-binding variants that behave like a paint. This can then be used to coat implants, devices, and injectable carriers to enable long-term local delivery without off-target effects.
“Our approach takes protein sequences that we discover using a lab-based test and optimizes them in several ways using our computational processes,” CEO Luis Alvarez (pictured below) told this publication…. Read more »
UNDERWRITERS AND PARTNERS
